*GMP (Good Manufacturing Practice) —rules that establish requirements for the organization of production and quality control of drugs for medical and veterinary use.
Nanolek is a Russian pharmaceutical company founded in 2011. We develop full-cycle production—from active pharmaceutical ingredient to finished dosage form—ensuring the country’s technological sovereignty in the prevention and treatment of socially significant diseases.
In 2020 the company was designated a systemically important enterprise of the Russian economy. By the end of 2024, Nanolek had entered the top-10 suppliers in Russia's tender-based pharmaceutical market. ₽15 billion planned investments in full-cycle vaccine localization through 2030.
Company
“Nanolek” has accumulated a unique experience in technology transfer:
more than 10 innovative drugs have been localized at the plant in the Kirov region in partnership with big pharma companies — world industry leaders.
800
employees
23% of which are engaged solely in quality control
20
drugs
in the portfolio. 7 more drugs are under development
15
billion rubles
planned investments in full-cycle vaccine localization through 2030
2.2
billion rubles
taxes paid to in the Kirov region over the past 5 years
NANOLEK IS A MEMBER OF ASSOCIATIONS
NANOLEK IS THE LEADER OF RATINGS
The mission
Protect people's lives and health by producing the world's best technologies, made available to everyone
Strategy
From the localization of the drugs of global pharmaceutical companies, to the biotech production of a full cycle and the development of innovative medicines “from scratch”
Partners
Our rule, without exception: All “Nanolek” partners are leaders in their field with impeccable reputations.
